healthcare professionals
Handelsbanken Liquidity Provider in Navamedic
Published 06. July 2021.
The Liquidity Provider scheme is based on standard agreements developed by the Norwegian Securities Dealers Association and reviewed by Oslo Børs. Handelsbanken Capital Markets has acted as financial advisor in connection with the listing of Navamedic ASA, and were also Manager in the share issue in Navamedic ASA in September 2005 when the company raised NOK 30 million in new equity.
For further information, please contact:
CFO Jon W. Ringvold, Navamedic
Office: +47 67 11 25 44 Mobile: +47 99 15 85 34
Erik Rønnov, Handelsbanken Capital Markets
Office: +47 22 94 09 44
About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world’s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. The company’s products will be sold through a network of sales, marketing and distribution partners. Navamedic’s product Glucomed® has been approved as a medicine against osteoarthritis in 20 European countries. The product was launched in Sweden in December 2005, and Navamedic prepares product launches in further European countries in 2006.
Handelsbanken Liquidity Provider in Navamedic
Stock Exchange Release - Published 30. March 2006.
The Liquidity Provider scheme is based on standard agreements developed by the Norwegian Securities Dealers Association and reviewed by Oslo Børs. Handelsbanken Capital Markets has acted as financial advisor in connection with the listing of Navamedic ASA, and were also Manager in the share issue in Navamedic ASA in September 2005 when the company raised NOK 30 million in new equity.
For further information, please contact:
CFO Jon W. Ringvold, Navamedic
Office: +47 67 11 25 44 Mobile: +47 99 15 85 34
Erik Rønnov, Handelsbanken Capital Markets
Office: +47 22 94 09 44
About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world’s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. The company’s products will be sold through a network of sales, marketing and distribution partners. Navamedic’s product Glucomed® has been approved as a medicine against osteoarthritis in 20 European countries. The product was launched in Sweden in December 2005, and Navamedic prepares product launches in further European countries in 2006.